Tag: Phase III TULIP® trial
First Patient Dosed in Phase 1 Study of Next Generation Antibody-Drug...
BYON3521, a new ADC targeting c-Met, has entered phase 1 (BYON3521.001/NCT05323045) clinical development when, earlier this week, a first patients had been dosed with the investigational drug being developed...
Trastuzumab Duocarmazine Granted U.S. FDA Fast Track Designation for Pre-treated HER2+...
The United States Food & Drug Administration (FDA) has granted Fast Track designation for The Netherlands-based Synthon Biopharmaceuticals investigational anti-HER2 antibody-drug conjugate or ADC...
